EEF1D Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T-lymphocyte line, designed for investigating the role of EEF1D in translation and transcription. The product provides a heterogeneous loss-of-function model with disrupted EEF1D expression, enabling functional studies without clonal selection.
Jurkat cells are a widely used human T-cell leukemia line originally isolated from the peripheral blood of a 14-year-old male with acute T-cell leukemia. They serve as a well-characterized model for T-cell signaling, leukemia biology, and apoptosis, making them ideal for studying oncogenic processes and drug responses. The immortalized nature and ease of genetic manipulation of Jurkat cells facilitate CRISPR-based knockout generation.
EEF1D encodes the delta subunit of the elongation factor-1 complex, functioning as a guanine nucleotide exchange factor for eEF1A to promote translation elongation. Additionally, EEF1D is a component of the P-TEFb complex (CDK9/Cyclin T1), which phosphorylates RNA polymerase II to stimulate transcriptional elongation, including of MYC. EEF1D activity is regulated by mTOR signaling and CK2-mediated phosphorylation, and it interacts with eEF1A, eEF1B subunits, valyl-tRNA synthetase, and P-TEFb components, linking nutrient sensing to global protein synthesis and gene expression.
In Jurkat cells, EEF1D knockout disrupts both translational and transcriptional elongation, potentially affecting leukemia cell growth, proliferation, and drug sensitivity. Given the central role of mTOR and MYC in T-cell leukemia, this model enables dissection of EEF1D-dependent mechanisms in cellular homeostasis and oncogenic signaling, offering a platform to study synthetic lethal interactions and validate EEF1D as a therapeutic target.
These polyclonal knockout cells are suitable for a range of assays, including Western blotting and RT-qPCR to confirm knockout, RNA-seq for transcriptomic profiling, puromycin incorporation and polysome profiling to assess translation, and functional assays such as proliferation, apoptosis, and drug sensitivity screening. Researchers can investigate translation regulation in T-cells, transcriptional elongation dynamics, and the role of EEF1D in leukemia, facilitating drug target validation and mechanistic studies. For further information, please contact Ascent Research.
